Pablo Rodríguez-Viciana

University College London (UCL), London, UK

Following a BSc by the Universidad Autonoma of Madrid, Spain, PR-V completed his PhD thesis in Julian Downward’s laboratory at the ICRF in London, where his work resulted in the identification of PI3K as a direct target of RAS and showed that RAS can use multiple effectors to signal downstream. He then carried out post-doctoral studies in Frank McCormick’s lab at the University of California, San Francisco, where his work led to the identification of the SHOC2 phosphatase complex as a unique regulatory node required for efficient RAS-ERK pathway activation with properties of an attractive therapeutic target. In 2008 he returned to London as a group leader at the UCL Cancer Institute where a major focus of his group is to study the function of the SHOC2 phosphatase complex in the context of diseases such as cancer and RASopathies.


15th september
15 September 2023

The SHOC2/MRAS/PP1 complex as a therapeutic target for RAS-driven cancers

15 September
Time:  10:00 - 10:30